BridgeBio Pharma, Inc.

NASDAQ:BBIO

Biotechnology

Healthcare
$78.01 +1.13%

+$0.75 today

Market cap
$15.20B
Beta
0.97
P/E (TTM)
-18.1
EPS (TTM)
-$3.73
52W Low $40.19High $84.94

Volume 3.55M

Average 2.49M

BBIO Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

BridgeBio Pharma, Inc.NASDAQ: BBIO

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit grows, but more slowly than its trailing trend

Q2 FY2026 gross profit of $228.63M rose 113.8% year over year, behind the +193.4% change in trailing-twelve-month gross profit. Sequentially, it rose 24.2% from the prior quarter. Over 3 fiscal years it compounded at +85.5% a year.

Context

  • Gross profit amounted to 94.4% of revenue in FY2025, down 3.9 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +113.8% toward the trailing-twelve-month pace of +193.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$228.63M+24.2% QoQ
Last fiscal yearDec 2025
$473.81M+117.3% YoY
LTMJun 2026
$665.62M+193.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+113.8%——
1 year+117.3%——
3-year CAGR+85.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
473.81M USD
Year-over-year change
+117.3%
4-year CAGR
+63.3%

Gross Profit vs competitors

How BBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +193.4% is the 2nd highest of 10, against a peer median of +11.3%.
  • Gross profit amounts to 93.3% of revenue for BBIO, versus a peer median of 82.9%.
BBIO Competitors
Gross Profit for BBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$821.17B USD+32536.1%+16.0%79.9%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$3.83B USD+86.0%+51.8%79.7%
ASNDAscendis Pharma A/SLTM Sep 2026€1.09B EUR+95.1%+147.0%90.6%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$942.72M USD-1.3%+17.4%98.2%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$828.57M USD-51.6%+36.4%82.1%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$665.62M USD+193.4%+85.5%93.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$559.44M USD+11.3%+19.0%83.6%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$394.98M USD-7.2%+66.0%60.7%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$18.41M USD-89.0%—92.0%
DNLIDenali Therapeutics Inc.LTM Jun 2026-$2.2M USD——61.0%
SRRKScholar Rock Holding CorporationLTM Sep 2026-$46.95M USD+53.0%—8236.0%
Peer median (excluding BBIO) —+11.3%+36.4%82.9%

Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue69.72M77.65M9.3M221.9M502.08M
Cost of Revenue3.11M3.43M2.45M3.88M28.27M
Gross Profit66.6M74.21M6.86M218.02M473.81M
Gross Margin95.5%95.6%73.7%98.3%94.4%
Research & Development451.02M399.46M455.71M506.46M477.54M
Selling, General & Admin192.21M143.19M150.59M288.93M555.14M
Operating Expenses643.23M586.42M614.23M811M1.04B
Depreciation & Amortization5.84M6.77M6.49M6.08M5.43M
EBITDA(533.83M)(397.44M)(565.47M)(436.83M)(676.45M)
EBITDA Margin-765.7%-511.9%-6078.3%-196.9%-134.7%
Operating Income(576.63M)(512.2M)(607.37M)(592.97M)(569.09M)
Operating Margin-827.1%-659.6%-6528.8%-267.2%-113.3%
Interest Income1.13M7.54M18.04M17.25M19.85M
Interest Expense46.78M80.44M81.29M99.29M53.1M
Other Income / Expenses(9.82M)27.55M(45.88M)50.78M(165.9M)
Income Before Tax(586.45M)(484.65M)(653.25M)(542.19M)(734.99M)
Pre-Tax Margin-841.2%-624.2%-7021.9%-244.3%-146.4%
Income Tax Expense0001.15M555K
Net Income(562.54M)(481.18M)(643.2M)(535.76M)(729.31M)
Net Margin-806.9%-619.7%-6913.9%-241.4%-145.3%
EPS (Basic)(3.90)(3.35)(3.95)(2.88)(3.79)
EPS (Diluted)(3.90)(3.35)(3.95)(2.88)(3.79)
Weighted Avg Shares144.36M147.47M162.79M186.08M197.24M
Weighted Avg Shares (Diluted)144.36M147.47M162.79M186.08M197.24M

BridgeBio Pharma, Inc.

NASDAQ:BBIO

Intrinsic Alpha fair value

Locked

Current Price

$78.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.